These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 11078469)

  • 1. Gliclazide modified release: from once-daily administration to 24-hour blood glucose control.
    Harrower A
    Metabolism; 2000 Oct; 49(10 Suppl 2):7-11. PubMed ID: 11078469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A rapid- and short-acting insulinotropic agent KAD-1229].
    Komatsu H; Ohnota H; Koizumi T; Satoh F
    Nihon Rinsho; 1997 Nov; 55 Suppl():171-9. PubMed ID: 9434463
    [No Abstract]   [Full Text] [Related]  

  • 3. Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes.
    Zhang H; Liu X; Kuang H; Yi R; Xing H
    Diabetes Res Clin Pract; 2007 Jul; 77(1):58-61. PubMed ID: 17118480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monotherapy of type 2 diabetes with once-daily gliclazide modified release in primary care.
    Ramachandran A
    Diabetes Res Clin Pract; 2003 Oct; 62(1):63-4. PubMed ID: 14581160
    [No Abstract]   [Full Text] [Related]  

  • 5. Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.
    Juhl CB; Pørksen N; Pincus SM; Hansen AP; Veldhuis JD; Schmitz O
    Diabetes; 2001 Aug; 50(8):1778-84. PubMed ID: 11473038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel rapid- and short-acting hypoglycemic agent, a calcium(2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and gliclazide.
    Ohnota H; Koizumi T; Tsutsumi N; Kobayashi M; Inoue S; Sato F
    J Pharmacol Exp Ther; 1994 May; 269(2):489-95. PubMed ID: 8182516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 24-hour glycemic profile in type 2 diabetic patients treated with gliclazide modified release once daily.
    Guillausseau PJ; Greb W
    Diabetes Metab; 2001 Apr; 27(2 Pt 1):133-7. PubMed ID: 11353879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gliclazide modified release: A critical review of pharmacodynamic, metabolic, and vasoprotective effects.
    Schernthaner G
    Metabolism; 2003 Aug; 52(8 Suppl 1):29-34. PubMed ID: 12939737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients.
    Feng Y; Mao G; Ren X; Xing H; Tang G; Li Q; Li X; Sun L; Yang J; Ma W; Wang X; Xu X
    Diabetes Care; 2008 Oct; 31(10):1939-44. PubMed ID: 18599530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic cause of hyperglycaemia and response to treatment in diabetes.
    Pearson ER; Starkey BJ; Powell RJ; Gribble FM; Clark PM; Hattersley AT
    Lancet; 2003 Oct; 362(9392):1275-81. PubMed ID: 14575972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of the glycaemic effects of sulfonylureas.
    Ashcroft FM
    Horm Metab Res; 1996 Sep; 28(9):456-63. PubMed ID: 8911983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Medication of the month. Gliclazide modified release (Uni Diamicron)].
    Scheen AJ
    Rev Med Liege; 2003 Oct; 58(10):641-5. PubMed ID: 14677526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Glimepiride].
    Nakamura N
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():351-6. PubMed ID: 12387017
    [No Abstract]   [Full Text] [Related]  

  • 14. [Sulfonylurea drugs for type 2 diabetes].
    Toyota T
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():339-45. PubMed ID: 12387015
    [No Abstract]   [Full Text] [Related]  

  • 15. Postreceptor effects of sulfonylurea on skeletal muscle glycogen synthase activity in type II diabetic patients.
    Bak JF; Schmitz O; Sørensen NS; Pedersen O
    Diabetes; 1989 Nov; 38(11):1343-50. PubMed ID: 2559864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacology of glimepiride].
    Satoh Y
    Nihon Rinsho; 1997 Nov; 55 Suppl():147-51. PubMed ID: 9434459
    [No Abstract]   [Full Text] [Related]  

  • 17. [Molecular basis of oral hypoglycemic sulfonylurea action].
    Owecki M; Horst-Sikorska W; Sowiński J
    Pol Merkur Lekarski; 2003 Nov; 15(89):445-8. PubMed ID: 14969140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Drugs stimulating insulin release. Importance of their use for improving glycemia, safety and quality of life in diabetes mellitus type 2].
    Sieradzki J
    Przegl Lek; 2000; 57(1):5-8. PubMed ID: 10907360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gliclazide modified release.
    McGavin JK; Perry CM; Goa KL
    Drugs; 2002; 62(9):1357-64; discussion 1365-6. PubMed ID: 12076188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel enhancer of insulinotrophic action by high glucose (JTT-608) stimulates insulin secretion from pancreatic beta-cells via a new cellular mechanism.
    Itabashi N; Okada K; Muto S; Fujita N; Ohta T; Miyazaki Ji ; Asano Y; Saito T
    J Pharmacol Exp Ther; 2001 Jun; 297(3):953-60. PubMed ID: 11356916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.